Skip to main content

Table 1 Base-case probabilities and cost estimates in the decision tree analysis

From: Cost-effectiveness analysis of neoadjuvant versus adjuvant chemotherapy for cT2-4N0-1 non-small cell lung cancer patients during initial treatment phase

Event Probability Source
NAC AC
Receiving surgery 1 1 Brandt et al. [10]
Receiving chemotherapy 1 1
Postoperative complication
 No ≥ 3 grade complication 0.82 0.91
 ≥ 3 grade complication 0.14 0.07
 Death 0.04 0.02
Adverse event of chemotherapy (> 3 grade) 0.15 0.38
OS 9.1 years 9.1 years